Because of the popularity of some third-generation cephalosporins, emergence of resistant organisms (e.g., selected Enterobacteriaceae) that produce inducible and extended-spectrum beta-lactamases has been a problem. Cefepime's twice-a-day dosage schedule and enhanced activity against Enterobacteriaceae and gram-positive organisms give it several advantages… (More)


Cite this paper

@article{Cunha1995Cefepime, title={Cefepime.}, author={Bernardo Cunha and Muzaffar Gill}, journal={The Medical clinics of North America}, year={1995}, volume={79 4}, pages={721-32} }